Document:

Exhibit 4.7

 

FORM
OF

AMENDMENT TO CONVERTIBLE PROMISSORY NOTE 

 

This AMENDMENT
TO CONVERTIBLE PROMISSORY NOTE (this “Amendment”) is made and entered into as of January __, 2016, by and among
Advanced Inhalation Therapies (AIT) Ltd. (the “Company”), a private company registered in Israel, and _____,
as Holder. Capitalized terms used but not defined herein shall have the meaning given to such terms in the Note (as defined below).

 

WHEREAS, the Company
previously issued and sold a convertible promissory note (the “Note”) to the Holder in the original aggregate
principal amount of $_____;

 

WHEREAS, Section 5 of
the Note provides the Holder with a certain participation right (the “Participation Right”) whereby the Holder
may receive an Option to purchase additional Ordinary Shares of the Company;

 

WHEREAS, the Company
is in the process of conducting an IPO, and it is acknowledged that the underwriters to the IPO have advised the Company that the
Participation Right may interfere with the consummation of an IPO;

 

WHEREAS, in order
to facilitate an IPO, the Company and the Holder desire to enter into this Amendment to amend the Note as set forth herein.

 

NOW, THEREFORE,
in consideration of the foregoing recitals and the mutual promises contained in this Amendment, and for other consideration, the
receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows:

 

		1.	Amendments.

 

		1.1.	Subject to the consummation of an IPO, the definition of “Conversion Shares” in the Note is hereby amended
and restated in its entirety to read as follows:

 

“Conversion Shares”
shall mean the Company’s Ordinary Shares to be issued to the investors in such transaction.

 

		1.2.	Subject to the consummation of an IPO, the definition of “Discounted Conversion Price” in the Note is hereby
amended and restated in its entirety to read as follows:

 

“Discounted Conversion
Price” shall mean the lowest price per share to be paid for the Company’s Ordinary Shares issued to any third party
or parties in such transaction (not including holders of the current series of Notes in connection with the conversion thereof),
multiplied by 39.5%.

 

		1.3.	Section 5 of the Note shall be deleted in its entirety. 

 

		2.	It is hereby acknowledged that the Company currently contemplates that, pursuant to the IPO, the Company will sell to investors
units (the “Units”) that consist of Ordinary Shares and warrants to purchase Ordinary Shares of the Company,
which said warrants shall have an exercise price per Ordinary Share equal to 125% of the price per Ordinary Share sold in such
IPO. In such an event, the Holder shall not have any right to receive such Units pursuant to a Mandatory Conversion under the Note,
and any securities other than Ordinary Shares shall not be taken into account in determining the Discounted Conversion Price. It
is further acknowledged that the Conversion Shares shall consist solely of Ordinary Shares similar to those issued in the IPO.
It is hereby clarified that the actual price and other terms relating to the securities to be offered in the IPO are subject to
change and will be determined immediately prior to the pricing in accordance with market conditions and per the underwriters and
the Company’s agreement.

 

    	 	 	 

     

    

 

For example, in the event that
in the IPO the Company sells to investors Units that consist of two Ordinary Shares and a Warrant to Purchase three Ordinary Shares
at a price per unit of $15.00, then for the sake of this example, the lowest price per share to be paid for the Company’s
Ordinary Shares shall be considered to be $7.50, and the Discounted Conversion Price will be $2.9625 = $7.50 X 39.5.

  

		3.	Governing Law. This Amendment and all questions relating to its validity, interpretation and performance shall be governed
by and construed in accordance with the laws of the state of Israel, without regard to conflicts of laws principles. Any dispute
arising under or in relation to this Agreement shall be resolved in the competent court situated in Tel Aviv, Israel, and each
of the parties hereby submits irrevocably to the exclusive jurisdiction of such court.

 

		4.	Severability. In the event that any provision of this Amendment becomes or is declared by a court of competent jurisdiction
to be illegal, unenforceable or void, this Amendment shall continue in full force and effect without said provision.

 

		5.	Terms of Note and Amendment. Except as expressly modified hereby, all terms, conditions and provisions of the Note shall
continue in full force and effect. In the event of any inconsistency or conflict between the Note and this Amendment, the terms
and conditions of this Amendment shall govern and control. This Note shall bind the Holder upon Holder’s execution hereof
and shall bind the Company subject to its execution hereof and the adoption of appropriate resolutions of the Company’s Board
of Directors and Shareholders, as required under applicable law.

 

		6.	Modification. This Amendment may not be altered, amended or modified in any way except by a written instrument referencing
this Amendment signed by the Company and the Holder.

 

		7.	Counterparts. This Amendment may be executed in counterparts, each of which shall be declared an original, but all of
which together shall constitute one and the same instrument. Delivery of an executed signature page of this Amendment by facsimile
transmission or by electronic transmission (including a .pdf delivered by electronic mail) will be as effective as delivery of
a manually executed counterpart hereof.

 

[Remainder
of page intentionally left blank, signature page follows]

 

 

 

    	 	2	 

     

    

 

IN WITNESS WHEREOF,
this Amendment has been executed and delivered on the date first above written.

 

 

 

	
        Company:

         

	ADVANCED INHALATION THERAPIES (AIT) LTD.
	
         

        By:

	Name:	Amir Avniel
	Title:	Chief Executive Officer

 

 

 

	
        Holder:

         

	 
	 
	 	 
	 	 

 

 

 

 

[Signature Page
to Amendment to Convertible Note]

 

 

 

    	 	3Exhibit
10.9

 

LICENSE
AGREEMENT BETWEEN CHONG CORPORATION AND 

 

VAPARIA
CORPORATION- “228 Patent” 

 

This
Agreement is made as of January 28, 2016, by and between

 

Chong
Corporation

a corporation organized under the laws of the State of Minnesota, with its

principal place of business at 5550 Nicollet Avenue, Minneapolis, MN 55419

(“Chong”)

 

-
and -

 

VapAria
Corporation 

a corporation organized under the laws of the State of Delaware, with its

principal place of business at 5550 Nicollet Avenue, Minneapolis, MN 55419

(“VapAria”).

 

WHEREAS:

 

	(a)	Chong
    is the assignee of US Patent No. 8,903,228 (the “‘228 Patent”); and
	 	 
	 (b)	Chong
    wishes to provide an exclusive license to VapAria, and VapAria wishes to obtain an exclusive license from Chong for the ‘228
    patent.

 

NOW,
THEREFORE, in consideration of the mutual covenants, conditions, and promises contained herein, the parties agree as follows:

 

Article
1.00

 

INTERPRETATION

 

	1.01	Definitions

 

The
following terms will have the following meanings:

 

(a)
“228 Patent” shall mean all rights in U.S. Patent License No. 8,903,228.

 

(b)
“Business Day” shall mean Monday to Friday inclusive, except statutory or civic holidays observed in the States
of Minnesota and Delaware.

 

(c)
“Product” means the purposes for which the license is granted, and refers specifically to the use of ‘228
the patent in any product or embodiment where the patent is employed and/or cited in the label.

 

(c)
“Territory” shall mean all jurisdictions recognized internationally.

 

(d)
“Term” shall mean the term of this Agreement as provided in Article 7.00 hereof.

 

(e)
“USPTO” shall mean the United States Patent and Trademark Office.

 

    	 	1	 

    	 	 	 

    

 

	1.02	Construction
    of Agreement

 

In
this Agreement:

 

	 	(a)	words
    denoting the singular include the plural and vice versa;
	 	 	 
	 	(b)	words
    importing the use of any gender shall include all genders;
	 	 	 
	 	(c)	the
    word “include”, “includes” or “including” shall mean “include/includes/including
    without limitation”;
	 	 	 
	 	(d)	when
    calculating the period of time within which or following which any act is to be done or step taken, the date which is the
    reference day in calculating such period shall be excluded. If the last day of such period is not a Business Day, the period
    shall end on the next Business Day;
	 	 	 
	 	(e)	all
    references to currency are to United States currency;
	 	 	 
	 	(f)	the
    division of this Agreement into separate articles, sections, subsections and exhibits, are for convenience of reference only
    and shall not affect the construction or interpretation of this Agreement; and
	 	 	 
	 	(g)	words
    or abbreviations which have well known or trade meanings are used herein in accordance with their recognized meanings.

 

ARTICLE
2.00

 

GRANT
OF LICENSE

 

	2.01	Grant
    of License 

 

Subject
to the terms and conditions of this Agreement, Chong hereby grants to VapAria an exclusive license for the ‘228 Patent for
the purpose of sublicensing and/or producing and marketing products under the license or a granted sublicense within the Territory
during the term. VapAria shall be permitted to sublicense the patent to any other party and such sublicense shall be honored by
Chong in the event that VapAria or its legal successor is dissolved, declares bankruptcy or is otherwise no longer able or willing
to pursue to the normal and anticipated course of its business activities. Furthermore, Chong will agree to bear all expenses
and costs associated with protecting the patent from infringement and/or from claims of infringement from other parties.

 

	2.02	Proprietary
    Rights

 

Subject
to the rights granted herein, Chong retains all of its rights, title and interests in and to all patent rights, inventions, copyrights,
know-how, and trade secrets relating to the ‘228 Patent except as otherwise expressly agreed between the parties. VapAria
retains all such rights in respect of additional development undertaken in accordance with this Agreement subsequent to the Effective
Date. Chong shall not sell, dispose, or alienate in any way its License Agreement without respecting VapAria’s legal rights
hereunder, and requiring any assignee to assume Chong’s obligations hereunder in a form satisfactory to VapAria.

 

    	 	2	 

    	 	 	 

    

 

ARTICLE
3.00

 

CHONG
REPRESENTATIONS AND WARRANTIES

 

	3.01	Representations
    and Warranties Generally

 

Chong
hereby makes the representations and warranties contained in this Article 3.00 to VapAria, and acknowledges that VapAria is relying
upon the accuracy of each such representation and warranty in connection with its entering into this Agreement.

 

	3.02	Power
    and Authority

 

Chong
has the right, full corporate power, and absolute authority to enter into this Agreement and to grant the rights herein described
to VapAria in the manner herein contemplated. Chong has taken all necessary or desirable actions, steps, and corporate or other
proceedings to approve or authorize, validly and effectively, the entering into, and the execution, delivery, and performance
of this Agreement and the granting of the rights herein described. This Agreement is a legal, valid, and binding obligation of
Chong, enforceable against Chong and VapAria in accordance with its terms.

 

	3.03	Intellectual
    Property

 

Chong
is the exclusive assignee of the ‘228 Patent and is authorized to license the ‘228 Patent. Chong has not received
any notice, complaint, threat, or claim alleging infringement of the ‘228 Patent or other intellectual property or proprietary
right of any other person in connection with the ‘228 Patent. There are no charges, encumbrances, pledges, security interests,
liens, actions, claims, demands or equities of any nature or kind, nor any rights or privileges capable of becoming any of the
foregoing, affecting the ‘228 Patent.

 

	3.04	No
    Other Obligations

 

No
person has or has made any claim or notification to Chong alleging any written or oral agreement, understanding or commitment,
or any right or privilege (whether by law or contractual) capable of becoming an agreement or commitment, to obtain rights in
and to the ‘228 Patent that would conflict with the rights herein granted to VapAria.

 

	3.05	Warranty
    Disclaimer

 

Chong
makes and VapAria receives no warranties of any kind, either expressed or implied, statutory or otherwise. Chong specifically
disclaims any and all implied warranties or conditions of merchantability, satisfactory quality or fitness for a particular purpose.

 

	3.06	Investment
    Representation

 

Chong
is acquiring the Consideration Shares for its own account with the present intention of holding such securities for purposes of
investment, and that it has no intention of distributing such Consideration Shares or selling, transferring or otherwise disposing
of such Consideration Shares in a public distribution, in any of such instances, in violation of the federal securities laws of
the United States of America.

 

ARTICLE
4.00

 

VAPARIA
REPRESENTATIONS, WARRANTIES, AND COVENANTS

 

	4.01	Representations,
    Warranties, and Covenants Generally

 

VapAria
hereby makes the representations, warranties, and covenants contained in this Article 3.00 to Chong, and acknowledges that Chong
is relying upon the accuracy of each such representation, warranty, and covenant in connection with its entering into this Agreement.

 

    	 	3	 

    	 	 	 

    

 

	4.02	Power
    and Authority

 

VapAria
has the right, full corporate power, and absolute authority to enter into this Agreement. VapAria has taken all necessary or desirable
actions, steps, and corporate or other proceedings to approve or authorize, validly and effectively, the entering into, and the
execution, delivery, and performance of this Agreement and the assumption of the obligations herein described. This Agreement
is a legal, valid, and binding obligation of VapAria, enforceable against VapAria and Chong in accordance with its terms.

 

	4.03	Diligence

 

VapAria
will make reasonable efforts to bring an embodiment of the Product to market in the Territory during the Term. In the event VapAria
does not make commercially reasonable efforts or VapAria or its affiliates license, produce, or otherwise market a competing product,
Chong will be entitled to terminate this Agreement as provided in Article 7.

 

	4.04	Patent
    Marking

 

VapAria
will mark all products sublicensed, manufactured or sold pursuant to this Agreement with the ‘228 patent number. The marking
will be in conformance with the patent laws and other laws of the country of manufacture or sale.

 

	4.05	Consideration
    Shares

 

The
Consideration Shares, when issued in accordance with the terms and conditions of this Agreement, will be fully paid and non-assessable.

 

ARTICLE
5.00

 

ONE
TIME FEE AND ROYALTIES

 

	5.01	One
    Time Fee

 

In
consideration for entering into this agreement, VapAria will issue Chong a one-time fee at closing in the form of 5 million shares
ofVapAria’s Common Stock (the “Consideration Shares”).

 

	5.02	Royalty
    Consideration

 

In
consideration for the rights granted to it, VapAria shall further pay royalties as described in this Article.

 

	5.02	Royalties

 

VapAria
shall pay to Chong a royalty in the amount of $50,000 per annum in the first calendar year, and for each year thereafter for the
remaining life of the patent, in which the patent is licensed and/or commercialized with an acknowledged embodiment and/or use.
Such acknowledgement shall be made in a mutually acknowledged notice between the assignee and the licensee.

 

	5.03	Audit

 

During
the term of this Agreement, and for a period of 18 months after any termination of it, VapAria shall keep accurate books of account
and all business records at its principal place of business covering all transactions subject to a license fee, royalty, or other
payment under this Agreement.

 

	5.04	Interest

 

Interest
shall accrue on amounts unpaid on their due dates hereunder at the rate of six (6%) percent per annum.

 

    	 	4	 

    	 	 	 

    

 

Article
6

 

INDEMNIFICATIONS

 

	6.01	Chong
    Indemnity

 

Chong
agrees to indemnify and hold VapAria harmless from and against all claims, demands, proceedings, losses, damages, liabilities,
deficiencies, costs and expenses (including all legal and other professional fees and disbursements, interest, penalties and amounts
paid in settlement) suffered or incurred by VapAria as a result of or arising directly or indirectly out of or in connection with:

 

	 	(a)	any
    breach by Chong of or any material inaccuracy of any representation or warranty of Chong contained in this Agreement; 
	 	 	 
	 	(b)	any
    breach or non-performance by Chong of any covenant to be performed by it that is contained in this Agreement; 
	 	 	 
	 	(c)	any
    breach arising from or relating to any use and distribution of the ‘228 Patent other than as expressly provided herein;
    and
	 	 	 
	 	(d)	infringement
    of any third party intellectual property rights in respect of the ‘228 Patent, other than any claim arising as a result
    of modifications to the product performed by or on behalf of VapAria.

 

Notwithstanding
the foregoing, in the event that the ‘228 Patent, or any part thereof is held to constitute an infringement on the intellectual
property of any third party, Chong, at its option and expense, may either (a) indemnify VapAria as above or (b) indemnify VapAria
from and against any damages for such pre-existing infringement, and (i) amend the Patent to make it non-infringing, (ii) procure
for VapAria the right to use the infringing materials, and/or (iii) replace the ‘228 Patent with other suitable noninfringing
rights having functionality that is substantially the same in all material respects to the ‘228 Patent.

 

	6.02	VapAria
    Indemnity

 

VapAria
agrees to indemnify and hold Chong harmless from and against all claims, demands, proceedings, losses, damages, liabilities, deficiencies,
costs and expenses (including all legal and other professional fees and disbursements, interest, penalties and amounts paid in
settlement) suffered or incurred by the Licensor as a result of or arising directly or indirectly out of or in connection with:

 

	 	(a)	any
    breach by VapAria of or any material inaccuracy of any representation or warranty of VapAria contained in this Agreement;
    
	 	 	 
	 	(b)	any
    breach or non-performance by VapAria of any covenant to be performed by it that is contained in this Agreement; 
	 	 	 
	 	(c)	any
    breach arising from or relating to any use and distribution of the product by VapAria other than as expressly provided herein;
    and
	 	 	 
	 	(d)	infringement
    of any third party intellectual property rights which infringement arises from modifications to the Product performed by or
    on behalf of the VapAria, except to the extent such claim is covered under section 7.01. 

 

	6.03	Indemnification
    Procedure

 

Any
party seeking indemnification under Article 6.00 (the “Indemnitee”) in respect of a third party claim shall
(i) promptly notify the indemnifying party (the “Indemnitor”) of such claim, (ii) provide the Indemnitor sole
control over the defense and/or settlement thereof, and (iii) at the Indemnitor’s request and expense, provide full information
and reasonable assistance to Indemnitor with respect to such claims. Without limiting the foregoing, with respect to third party
claims brought under Sections 6.01 and 6.02, the Indemnitee, at its own expense, shall have the right to participate with counsel
of its own choosing in the defense and/or settlement of any such claim.

 

    	 	5	 

    	 	 	 

    

 

Article
7.00

 

TERM
AND TERMINATION

 

	7.01	Term

 

The
term of this Agreement shall be for the life of the patent commencing on the date of execution of this Agreement, and shall continue
in full force and effect unless terminated in accordance with this Article 7.00.

 

	7.02	Termination
    for Cause

 

Either
party may terminate this Agreement for cause as follows:

 

7.02.1
Nonpayment

 

If
either party fails to pay any amount due hereunder to the other party within five (5) Business Days after the non-defaulting party
gives the defaulting party written notice of such nonpayment, the non-defaulting party shall have the right to terminate this
Agreement immediately upon the expiration of such five (5) Business Day period.

 

7.02.2
Non-Monetary Default

 

If
any representation or warranty provided for herein proves to be materially inaccurate, or if either party breaches any non-monetary
covenant provided for herein or defaults in the performance of any non-monetary term, condition, or provision of this Agreement
and the default is not cured within thirty (30) days (if capable of being cured within that time) after the non-defaulting party
gives written notice to the defaulting party of such default, the non-defaulting party shall have the right to terminate this
Agreement immediately upon the expiration of such thirty (30) day period. If the nature of the default is such that more that
thirty (30) days are required for cure, the non-defaulting party shall have the right to terminate upon written notice if the
defaulting party fails to commence efforts to cure such default within the thirty (30) day period and in any event such cure is
not completed within 75 days of the commencement of such 30 day period.

 

	7.03	Effect
    of Termination for Cause

 

	(a)	Upon
    the termination of this Agreement by VapAria for cause, the following provisions shall take effect:

 

	 	(i)	The
    rights and licenses granted to VapAria under this Agreement shall survive, subject to the limitations set forth herein, and
    VapAria shall be entitled to continue its use of the ‘228 Patent; and
	 	 	 
	 	(ii)	The
    indemnity and outstanding payment obligations hereunder existing at the time of termination, shall survive.
	 	 	 
	 	(iii)	VapAria
    shall have such other rights and remedies for damages as provided by law.

 

    	 	6	 

    	 	 	 

    

 

	(b)	Upon
    the termination of this Agreement by Chong for cause, the following provisions shall take effect:

 

	 	(i)	The
    rights and licenses granted to VapAria under this Agreement shall be terminated, subject to subsection (ii) below; and
	 	 	 
	 	(ii)	Any
    and all Product manufactured by or for VapAria prior to the effective date of such termination and in accordance with the
    terms and conditions herein shall not be deemed a violation of this Agreement; and
	 	 	 
	 	(iii)	Chong
    shall have such other rights and remedies for damages as provided by law.

 

ARTICLE
8.0

 

CONFIDENTIAL
INFORMATION

 

The
parties agree that all information forwarded to one by the other for the purposes of this Agreement: (1) are to be received in
strict confidence, (2) are to be used only for the purposes of this Agreement, and (3) are not to be disclosed by the recipient
party, its agents or employees without the prior written consent of the other party, except to the extent that the recipient party
can establish competent written proof that such information:

 

	 	a)	was
    in the public domain at the time of disclosure;
	 	 	 
	 	b)	later
    became part of the public domain through no act or omission of the recipient party, its employees, agents, successors or assigns;
	 	 	 
	 	c)	was
    lawfully disclosed to the recipient party by a third party having the right to disclose it;
	 	 	 
	 	d)	was
    already known by the recipient party at the time of disclosure;
	 	 	 
	 	e)	was
    independently developed by the recipient; or
	 	 	 
	 	f)	is
    required by law or regulation to be disclosed, provided however, that the disclosing party shall first give the other party
    written notice and adequate opportunity to object to such order for disclosure or to request confidential treatment.

 

    	 	7	 

    	 	 	 

    

 

Information
shall not be deemed to be available to the public or to be in the recipient’s possession merely because it:

 

	 	a)	includes
    information that falls within an area of general knowledge available to the public or to the recipient (i.e., it does not
    include the specific information provided by the other party); or
	 	 	 
	 	b)	can
    be reconstructed in hindsight from a combination of information from multiple sources that are available to the public or
    to the recipient, if not one of those sources actually taught or suggested the entire combination, together with its meaning
    and importance.

 

Each
party’s obligation of confidence hereunder shall be fulfilled by using at least the same degree of care with the other party’s
confidential information as it uses to protect its own confidential information. This obligation shall exist while this Agreement
is in force and for a period of 3 years thereafter.

 

Article
9.00

 

GENERAL

 

	9.01	Governing
    Law and Jurisdiction

 

This
agreement shall be governed by and construed under the laws of the State of Minnesota, without reference to conflict of laws principles.
The parties agree that any dispute arising under this Agreement or out of the negotiation of or the relationship that is being
formed pursuant to this Agreement will only be venued in the State or Federal Courts of Minnesota, and hereby consent to such
jurisdiction and venue.

 

	9.02	Assignment

 

To
the extent this Agreement is assigned to another either pursuant to this Agreement or by operation of law, this Agreement shall
be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.

 

	9.03	Notices

 

Any
notice, demand, or other communication (“Notice”) required or permitted to be given or made shall be in writing
and shall be sufficiently given or made if delivered in person, sent by facsimile transmission, or sent by prepaid first class
registered mail during normal business hours on a Business Day and addressed as follows:

 

	 	to
    Chong:	Chong
    Corporation
	 	 	5550
    Nicollet Avenue S.
	 	 	Minneapolis,
    MN 55419
	 	 	Attention:
    Alexander C. Chong
	 	 	 
	 	to
    VapAria:	VapAria
    Corporation
	 	 	5550
    Nicollet Avenue S.
	 	 	Minneapolis,
    MN 55419
	 	 	Attention:
    William P. Bartkowski

 

or
to such other person or address as a party may from time to time advise the other party by Notice in writing pursuant to the provisions
of this Section. The date of receipt of any such Notice, demand or request shall be deemed to be the date of delivery or facsimile
of such Notice, demand, or request if served personally, faxed on a Business Day during normal business hours, or if sent after
normal business hours of the recipient then the next Business Day, or, if mailed as aforesaid, the third Business Day following
the date of mailing.

 

    	 	8	 

    	 	 	 

    

 

	9.04	Entire
    Agreement

 

The
parties hereto acknowledge that this Agreement and its Schedules set forth the entire agreement and understanding of the parties
hereto as to the subject matter hereof, and supersedes all prior discussions, agreements and writings in respect hereto, including
the Letter of Intent.

 

	9.05	Counterparts

 

This
Agreement may be executed in any number of counterparts and when so executed and delivered shall have the same force and effect
as though all signatures appeared on one document.

 

	9.06	Further
    Assurances

 

Each
party covenants and agrees to do and cause all things to be done and execute and deliver all such documents as may be required
in order to carry out the provisions of this Agreement. 

 

	9.07	Severability

 

The
provisions of this agreement shall be severable, and if any provision of this Agreement shall be held or declared to be illegal,
invalid, or unenforceable, such illegal, invalid or unenforceable provision shall be severed from this Agreement and the remainder
of this Agreement shall remain in full force and effect, and the parties shall negotiate a substitute, legal, valid and enforceable
provision that most nearly reflect the parties’ intent in entering into this Agreement.

 

IN
WITNESS WHEREOF, the parties, by their duly authorized representatives, have entered into this Agreement.

 

	CHONG
    CORPORATION	 	VAPARIA
    CORPORATION
	 	 	 
	By:
    	/s/Alexander
    C. Chong	 	By:
    	/s/William
    P. Bartkowski 
	 	 	 	 	 
	Name:
    	Alexander
    C. Chong	 	Name:
    	William
    P. Bartkowski
	 	 	 	 	 
	Title:
    	Chief
    Executive Officer	 	Title:
    	President
    
	 	 	 	 	 
	Date:
    	January
    28, 2016	 	Date:
    	January
    28, 2016 

 

    	 	9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]